ArticleCase reports in oncology
Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.Frontiers in immunology · 2020Pooled it
- Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.American journal of hematology · 2019Trial
- Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.Frontiers in immunology · 2025Article
- Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.Frontiers in pharmacology · 2025Article
- Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management.Pharmaceutical medicine · 2024Review
- Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma.The American journal of case reports · 2023Review
- Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.Translational lung cancer research · 2022Article
- Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.Thoracic cancer · 2020Article
- Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.Thoracic cancer · 2020Article
- Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.Cancer management and research · 2020Article
- Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.Melanoma management · 2019Review
- Pembrolizumab-associated autoimmune haemolytic anaemia.BMJ case reports · 2019Article
- [Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Hematologic Complications of Immune Checkpoint Inhibitors.The oncologist · 2019Article
- Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.Internal medicine (Tokyo, Japan) · 2019Article
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.Drug safety · 2019Review
- Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia.Frontiers in pharmacology · 2019Review
- Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.Blood advances · 2018Article
- Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.Journal for immunotherapy of cancer · 2018Article
- Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.Haematologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of patients with metastatic squamous cell skin cancer, refractory to initial therapy with standard chemotherapy and radiation protocols, remains difficult with poor overall prognosis and limited therapeutic options. Recently, promising response rates with nivolumab, a programmed death receptor-1-blocking antibody, in squamous cancer of the head and neck have been demonstrated. Considering the similar histological patterns of squamous cell cancer of the skin and squamous cell cancer of the head and neck, we assumed that nivolumab could also be effective in our patients with refractory metastatic squamous cell cancer of the skin. So far, there have been no clinical data on the therapeutic efficacy of nivolumab in squamous cell skin cancer. We here present a case of a patient with metastatic squamous cell skin cancer refractory to previous therapies, who showed a good response to nivolumab over a period of 5 months, but developed a serious hemolytic crisis under nivolumab treatment after eight applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.